Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Efficacy of Zamicastat in PAH
NCT04316143Phase 2Completed
- Sponsor
- BIAL
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH), sponsored by BIAL. Primary endpoints: Area Under the Curve 0-24h, Maximum Plasma Concentration and 2 more. Started Jun 2019; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04316143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316143.